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Background.**Australian*national*biomonitoring*for*persistent*organic*pollutants*49* (POPs)*relies*upon*age>specific*pooled*serum*samples*to*characterize*central*50* tendencies*of*concentrations*but*does*not*provide*estimates*of*upper*bound*51* concentrations.**This*analysis*compares*population*variation*from*biomonitoring*52* datasets*from*the*US,*Canada,*Germany,*Spain,*and*Belgium*to*identify*and*test*53* patterns*potentially*useful*for*estimating*population*upper*bound*reference*values*54* for*the*Australian*population.***55*
Methods.**Arithmetic*means*and*the*ratio*of*the*95th*percentile*to*the*arithmetic*mean*56* (P95:mean)*were*assessed*by*survey*for*defined*age*subgroups*for*three*polychlorinated*57* biphenyls*(PCBs*138,*153,*and*180),*hexachlorobenzene*(HCB),*p,p>58* dichlorodiphenyldichloroethylene*(DDE),*2,2’,4,4’*tetrabrominated*diphenylether*(PBDE*59* 47),*perfluorooctanoic*acid*(PFOA)*and*perfluoroctane*sulfonate**(PFOS).****60*


















degrees*of*variation*in*biomarker*concentrations*in*different*populations,*even*when*the*122* absolute*levels*of*exposure*differ.**Specifically,*variations*in*biomarker*concentrations*of*123* persistent*compounds*within*a*population*and*age*group*that*are*exposed*to*a*given*124* matrix*of*environmental*concentrations*usually*are*controlled*by*a*few*factors.**These*125* include*interindividual*variation*in*metabolism*and*elimination*rates,*interindividual*126* variation*in*long>term*exposure*rates*(for*example,*high*fat*vs.*low*fat*diet,*for*lipophilic*127* compounds),*history*of*breast*feeding,*and,*in*the*case*of*lipophilic*compounds,*128* interindividual*variation*in*lipid*content*of*blood*(Bernert*et*al.*2007;*Phillips*et*al.*1989;*129* Porta*et*al.*2009).**The*net*effect*of*these*factors*on*the*degree*of*variation*of*biomarker*130* concentrations*may*be*similar*across*different*populations,*even*if*absolute*exposure*131* levels*are*not.*132* *133* This*project*examined*available*biomonitoring*datasets*from*the*US*National*Health*and*134* Nutrition*Examination*Survey*(NHANES),*the*Canadian*Health*Measures*Survey*(CHMS),*135* the*German*Environmental*Survey*(GerES),*the*Catalan*Health*Interview*Survey*(CHIS),*136* and*the*Flemish*Environmental*Health*Survey*II*(FLEHS*II)*to*inform*interpretation*of*the*137* Australian*pooled*biomonitoring*data.**The*objectives*of*the*present*study*were*to:***138*
• Compare*population*subgroup*arithmetic*mean*concentrations*of*the*subject*139* analytes* in* Australian* pools* to* those* observed* in* datasets* from* the* US,*140* Canada,*Germany,*and*Catalonia;*and**141*




We*use*the*results*of*this*analysis*to*estimate*population*95th*percentiles*(with*144* confidence*limits)*for*the*Australian*age*groups*based*on*the*pooled*sample*means*145* and*discuss*the*estimated*levels*in*the*context*of*health*risk*screening*values,*146* where*available.*147* *148*
2! Methods!149*

















The*Flemish*Environment*and*Health*Survey*II*(FLEHS*II)*examined*the*234* concentrations*of*numerous*analytes*in*newborns,*their*mothers,*and*in*235* adolescents*(Schoeters*et*al.*2011;*Schroijen*et*al.*2008;*Staessen*et*al.*2001).***236* *Concentrations*of*all*of*the*target*analytes*for*this*evaluation*were*measured*in*237* representative*samples*of*cord*blood*plasma*in*newborns*and*women*of*238* reproductive*age*(through*age*45)*in*2008>2009*and*in*adolescents*from*2008>239* 2011.***Concentrations*of*PFOA*and*PFOS*were*also*measured*in*young*adults*240* through*age*40*in*2008>2011*(Schoeters*et*al.*2011).*241* *242*
2.3$ Statistical$analysis$243* The*primary*goal*of*this*analysis*was*to*provide*information*that*could*be*used*to*244* estimate*a*95th*percentile*for*Australian*population*subgroups*by*age*based*on*the*245* pooled*sampling*effort*conducted*periodically*in*Australia.**For*the*Australian*246* pooled*analyses,*pools*are*assembled*for*six*age*groups:**0*to*4,*5*to*15,*16*to*30,*31*247* to*45,*46*to*60,*and*>=61*years.**Thus,*for*these*analyses,*each*of*the*included*248* datasets*was*stratified*into*corresponding*age*groups.**249* *250*




ratio*were*calculated*using*the*appropriate*dataset>specific*survey*sample*weights.**257* Then*that*age*stratum*was*resampled*with*replacement*1,000*times.**For*each*258* iteration,*the*arithmetic*mean*and*the*P95:mean*ratio*were*calculated*using*the*259* appropriate*weights*and*recorded.**The*2.5th*and*97.5th*percentiles*of*the*resulting*260* 1,000*estimates*for*the*mean*and*P95:mean*ratio*were*then*selected*as*the*95%*261* confidence*intervals*on*the*point*estimates*of*the*“true”*mean*and*P95:mean*ratios.**262* All*analyses*were*conducted*using*Stata*12.1,*except*for*those*on*the*CHMS*dataset,*263* which*was*analyzed*by*scientists*at*Statistics*Canada*using*SAS*9.2*and*SUDAAN*264* 10.0.1*as*a*SAS>callable*extension.**In*addition,*the*analysis*of*the*CHMS*dataset*265* analyses*relied*upon*the*previously>established*bootstrap*replicate*weights*for*that*266* dataset,*which*provide*500*rather*than*1,000*iterations*of*the*calculation.**267* *268* Arithmetic*means*for*each*analyte*and*age*group*were*compared*across*269* populations.**The*observed*P95:mean*ratios*were*examined*for*patterns*across*270* surveys*and*across*age*groups*through*visual*inspection,*including*consideration*of*271* the*width*and*overlap*of*confidence*intervals.***272* *273*








population>representative*datasets*allowed*estimation*of*ratios*for*ages*0*to*4,*so*303* ratios*obtained*for*the*5>15*yr*age*group*were*applied*to*the*mean*concentrations*304* calculated*for*cord*blood*data*from*the*FLEHS*II*dataset*to*estimate*the*305* corresponding*95th*percentiles.**Similarly,*no*unified*ratio*estimate*was*available*for*306* PBDE*47,*PFOA,*or*PFOS,*so*the*ratios*from*the*most*recent*NHANES*survey*data*307* (2003>2004*for*PBDE*47*and*2009>2010*for*the*PFCs)*were*used*for*those*analytes.*308* The*predicted*95th*percentile*and*confidence*intervals*for*each*age*group*and*309* analyte*was*compared*to*the*true*95th*percentile*to*evaluate*if*the*distributions*310* observed*in*the*other*datasets*could*accurately*predict*the*upper*end*of*the*311* observed*distribution*in*the*FLEHS*II*dataset*based*on*the*arithmetic*mean*312* measures*in*that*dataset.*313* *314*
2.4$ Prediction$of$95th$percentiles$for$the$Australian$population$and$comparison$to$315*





3! Results!327* Each*of*the*datasets*included*in*this*analysis*covered*somewhat*different*age*ranges*328* and*numbers*of*sampled*participants*(Table*1).**Because*the*purpose*of*the*analysis*329* is*to*inform*the*interpretation*of*the*Australian*pooled*biomonitoring*surveys,*age*330* groups*were*defined*using*the*same*cutpoints*used*by*the*Australian*sampling*331* program.**Data*representing*the*youngest*age*group*(0*to*4*years)*was*not*available*332* for*these*analytes*from*any*of*the*available*datasets,*although*arguably*the*cord*333* blood*data*collected*in*the*FLEHS*II*may*be*most*relevant.**The*coverage*of*the*5>to>334* 15*age*group*was*only*partial,*with*substantial*overlap*in*the*GerES*IV*dataset*(ages*335* 7*to*14*included)*and*partial*overlap*in*the*NHANES*datasets*(12*to*15).***Similarly,*336* the*cutoff*ages*at*the*upper*end*varied*by*dataset.**337* *338*




age*group*for*each*compound*allow*examination*of*potential*trends*in*this*metric*349* with*age*with*each*survey*as*well*as*evaluation*of*the*consistency*of*results*among*350* surveys.**Tables*of*population*statistics*for*each*survey*are*available*in*351* Supplementary*Data.*352* *353*




included*surveys*that*present*data*on*a*lipid>adjusted*basis,*and*at*least*some*of*the*372* difference*in*arithmetic*means*between*this*survey*and*the*current*Australian*373* pooled*data*is*due*to*the*likely*decrease*in*levels*over*time*in*the*environment*and*374* in*the*population*since*the*CHIS*was*conducted.**The*US*and*Canadian*datasets*375* generally*exhibited*similar*arithmetic*mean*concentrations*at*each*age*group,*with*376* the*means*intermediate*between*the*Australian*and*CHIS*mean*concentrations.*377* *378* In*contrast*to*the*results*for*the*arithmetic*means,*the*P95:mean*ratios*observed*for*379* each*PCB*compound*were*relatively*similar,*both*across*age*groups*and*among*the*380* different*surveys.***P95:mean*ratios*for*all*three*compounds*were*generally*381* between*2*and*2.5,*without*any*clear*or*consistent*patterns*of*difference*by*age*or*382* survey.**The*only*exception*was*for*PCB*180*for*the*age*group*5*to*15*years.**Data*383* from*the*GerES*IV*and*NHANES*survey*both*suggest*that*the*P95:mean*ratio*is*384* approximately*3*for*this*analyte*in*this*age*group,*somewhat*higher*than*observed*385* in*the*older*age*groups.***386* *387*




surveys*at*each*age*group.**In*contrast,*DDE*mean*concentrations*were*somewhat*395* higher*in*the*Catalan*data*compared*to*the*other*surveys*(Porta*et*al.*2010;*Porta*et*396* al.*2012).*397* *398* The*P95:mean*ratios*from*the*different*surveys*were*not*as*consistent*for*HCB*as*399* for*the*PCB*compounds,*varying*both*within*and*between*age*groups*among*the*400* different*surveys*over*a*range*from*about*1.5*to*2.5.**In*particular,*the*NHANES*401* dataset*had*lower*ratios*for*each*of*the*adult*age*groups*compared*to*the*other*402* surveys,*although*the*ratio*for*the*5>15*age*group*was*similar*to*that*observed*in*403* the*GerES*IV*dataset.**For*DDE,*the*P95:mean*ratios*were*also*somewhat*less*404* consistent,*without*a*clear*pattern*either*across*age*groups*or*surveys.**Overall,*the*405* DDE*ratios*were*higher*than*those*observed*for*the*other*analytes,*ranging*from*406* approximately*2*to*3.5.***407* *408*




temporal*trend*of*declining*exposures*over*time*and*more*active*metabolism*of*this*418* compound,*resulting*in*somewhat*shorter*half>life*of*elimination*(Quinn*and*Wania,*419* 2012).****420* *421* P95:mean*ratios*were*available*only*from*the*NHANES*and*CHMS*surveys*and*did*422* not*present*a*consistent*pattern,*either*within*or*between*age*groups.**Ratios*423* ranged*from*approximately*2.7*to*nearly*5.**Both*of*these*datasets*represent*North*424* American*populations,*where*exposure*to*brominated*flame*retardants*has*been*425* substantially*higher*than*in*European*and*other*populations*(Harrad*et*al.*2010;*426* Roosens*et*al.*2009).**As*noted*above,*PBDE*47*is*actively*metabolized,*and*thus*427* variations*in*individual*efficiency*of*metabolism*may*vary*somewhat*more*than*for*428* the*more*passive*elimination*mechanisms*that*dominate*for*the*chlorinated*429* compounds*discussed*above.**In*addition,*indoor*dust*may*be*a*more*important*430* exposure*pathway*for*brominated*flame*retardants*compared*to*PCBs*and*OCPs,*431* potentially*resulting*in*more*variable*exposure*levels*within*populations.***432* *433*




all*of*the*more*recent*datasets,*again,*with*no*striking*trend*by*age*group.***441* P95:mean*ratios*are*quite*similar*among*all*age*groups*for*PFOA,*ranging*between*442* approximately*1.7*and*2.2.**For*PFOS,*there*is*somewhat*more*variation,*but*overall,*443* the*ratios*again*range*fairly*narrowly,*from*about*1.7*to*2.6.***444* *445*




inconsistencies*in*results*across*surveys*and*across*and*within*age*groups,*it*is*464* difficult*to*identify*any*specific*dataset*that*would*be*most*appropriate*to*465* recommend*for*use*as*a*model*for*the*P95:mean*ratio*for*estimating*the*95th*466* percentile*in*the*Australian*population*data*based*on*the*pooled*results*for*this*467* compound.**In*the*absence*of*a*more*consistent*set*of*ratios,*the*age*group>specific*468* US*NHANES*P95:mean*ratios*for*PBDE*47*were*applied*to*estimate*95th*percentile*469* concentrations*in*the*FLEHS*II*survey*(as*a*validation*exercise)*and*for*the*470* Australian*population*based*on*their*pooled*sample*data.*471* *472* Three*datasets*were*examined*for*PFOS*and*PFOA.**As*discussed*above,*the*CHMS*473* bootstrapped*iterations*were*not*available*for*inclusion*in*a*unified*analysis.*474* However,*because*the*observed*P95:mean*ratios*across*the*two*NHANES*surveys*(a*475* decade*apart)*and*the*CHMS*survey*were*quite*consistent*both*within*and*between*476* age*groups,*the*results*from*the*most*recent*NHANES*survey*are*proposed*as*477* providing*a*reasonable*estimate*of*the*P95:mean*ratio*for*use*with*these*478* compounds.**These*are*presented*in*Table*3.*479* *480*








between*populations.**However,*the*results*here*do*support*the*idea*that,*at*least*in*510* some*circumstances,*cord*blood*sampling*and*analysis*for*the*purposes*of*511* population*characterization*could*be*conducted*using*pooled*samples*without*loss*512* of*too*much*information,*thus*maximizing*the*utility*of*the*limited*sample*volumes*513* available.*514* *515*
3.4$ Prediction$of$Australian$Population$Upper$Bound$Reference$Values$and$516*




travail*(ANSES)*based*on*studies*relating*human*health*outcomes*to*serum*lipid*533* PCB*concentrations*(Agence*nationale*de*securite*sanitaire*Alimentation*534* Environnement*Travail*(ANSES)*2010).**No*health*risk>based*screening*values*535* based*on*biomarker*concentrations*were*found*for*the*other*chemicals*in*this*536* analysis.*537* *538*




range*of*5*to*83*ng/g*lipid.**These*levels*are*consistent*with*BE*values*556* corresponding*to*cancer*risk*estimates*in*the*range*of*1*in*1*million*to*1*in*100,000*557* (Aylward*et*al.*2010).**This*range*of*cancer*risk*is*generally*considered*by*the*558* USEPA*to*be*in*the*target*range*for*acceptable*risks.****559*
$560*
DDE.$$BE*values*for*summed*DDT*and*metabolites*DDE*and*DDD*in*serum*lipid*are*561* available*(Kirman*et*al.*2011).**Generally*DDE*is*the*predominant*contributor*to*this*562* sum.**For*noncancer*endpoints,*the*BE*value*corresponding*to*the*USEPA*reference*563* dose*(RfD,*which*is*also*derived*based*on*rat*hepatic*toxicity*data)*is*5,000*ng/g*564* lipid.**The*Australian*pool*means*range*from*83*to*665*ng/g*lipid,*and*P95*estimates*565* range*from*245*to*approximately*2,000*ng/g*lipid,*and*so*are*below*the*non>cancer*566* BE*value.***Based*on*estimates*of*cancer*risk*derived*from*rat*bioassay*data,*the*567* highest*Australian*P95*(for*age*group*>60*yrs)*corresponds*to*an*estimated*cancer*568* risk*of*5*in*100,000,*while*the*lowest*pool*mean*value*corresponds*to*an*estimated*569* cancer*risk*level*of*2.5*in*1*million.***570* *571*




1,800*ng/g*lipid*would*be*protective.**These*values*are*calculated*as*the*sum*of*PCB*579* 138,*153,*and*180*times*a*factor*of*1.7.***580* *581* In*the*Australian*pooled*data,*we*do*not*have*a*direct*assessment*of*the*sum*of*PCBs*582* 138,*153,*or*180*at*the*P95.**However,*a*conservative*approach*would*be*to*sum*the*583* P95*estimates*for*the*three*congeners*and*multiply*this*sum*by*1.7.**When*584* calculated*this*way,*none*of*the*Australian*age*groups*approach*the*ANSES*585* concentrations*of*concern,*suggesting*relatively*little*concern*based*on*the*current*586* health*risk*assessments*for*PCBs.***587* *588*
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Table!2:!!Unified!P95:mean!ratios!based!on!NHANES,!GerES,!and!CHIS!datasets!by!age!group!and!overall!for!PCBs!138,!153,!and!824! 180;!HCB;!and!DDE.!825! !! Unified!P95:mean!ratio!(95%!CI)!Age!Group! PCB!138! PCB!153! PCB!180! HCB! DDE!5H15! 2.40!(2.09H2.67)! 2.51!(2.05H3.77)! 2.91!(2.19H5.44)! 1.87!(1.62H2.46)! 3.11!(2.4H4.72)!16H30! 2.25!(1.99H2.73)! 2.23!(1.86H2.86)! 2.40!(1.78H3.04)! 2.23!(1.63H2.93)! 2.56!(1.97H3.66)!31H45! 2.06!(1.81H2.57)! 2.06!(1.89H2.45)! 2.09!(1.87H3.44)! 2.51!(1.53H3.04)! 2.69!(2.14H3.55)!46H60! 2.08!(1.74H2.93)! 2.14!(1.92H2.78)! 2.00!(1.72H2.49)! 2.43!(1.44H2.91)! 3.16!(2.63H3.86)!61+! 2.14!(1.64H3.12)! 2.23!(1.73H3.01)! 2.05!(1.71H2.98)! 2.41!(1.62H3.27)! 3.11!(2.51H3.83)!






P95:mean!Ratio!(95%!CI)!by!Age!Group!Source!0H4! 5H15! 16H30! 31H45! 46H60! 61+!PCB!138! 2.2!(1.8H3)!Unified!AllHAges!(Table!2)!PCB!153! 2.18!(1.8H2.9)!Unified!AllHAges!(Table!2)!PCB!180! 2.12!(1.8H3.4)!Unified!AllHAges!(Table!2)!HCB! 2.3!(1.5H3.0)!Unified!AllHAges!(Table!2)!DDE! 3.0!(2.1H3.9)!Unified!AllHAges!(Table!2)!PBDE!47! 3.3!(2.3H4.1)!NHANES!2003H2004!Ages!12H15! 3.3!(2.3H4.1)!NHANES!2003H2004!Ages!12H15! 3.2!(2.5H4.2)!NHANES!2003H2004!AgeHspecific! 2.7!(1.9H3.5)!NHANES!2003H2004!AgeHspecific!
!
4.8!(3.4H7)!NHANES!2003H2004!AgeHspecific! 4.2!(3.3H5)!NHANES!2003H2004!Ages!61H80!PFOA! 1.8!(1.6H2.0)!NHANES!2009H2010!Ages!12H15! 1.8!(1.6H2.0)!NHANES!2009H2010!Ages!12H15! 2.0!(1.9H2.3)!NHANES!2009H2010!AgeHspecific! 2.2!(2.0H2.5)!NHANES!2009H2010!AgeHspecific! 2!(1.7H2.5)!NHANES!2009H2010!AgeHspecific!
!
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( ( (PBDE(47( 014( 6.3((4.917.8)(( 21.1((14.6125.7)((









( ( (PFOA( 014( 5.2((3.217.1)(( 9.2((8.3110.1)((









( ( (PFOS( 014( 5.7((3.517.8)(( 13.2((10.9117.5)((


















HCB( MRL,(ATSDR,(2002( 5E105(mg/kg1d( Hepatic(toxicity(in(
rats(
47(ng/g(lipid( (




































S1),!the!CHIS!(Table!S2),!NHANES!(Table!S3),!CHMS!(Table!S4),!and!FLEHS!II!(Table!S5)!are!884! presented!here.!885! !886! Table!S1:!Arithmetic!mean!(AM),!geometric!mean!(GM),!geometric!standard!deviation!887! (GSD),!95th!percentile!(p95),!and!P95:AM!ratios!from!the!German!Environmental!Survey!888! (GerES).!!Note!that!for!age!group!7D14!data!are!from!GerES!IV,!from!samples!collected!from!889! 2003D2006,!while!the!data!for!the!remaining!age!groups!was!from!the!GerES!III,!conducted!890! in!1998.!!Concentrations!measured!in!whole!blood.!891! !892!
Compound( Age(Group( AM((95%CI)( GM( GSD( p95( P95:AM(ratio((95%(CI)(
PCB(138( 7114( 0.11((0.11,(0.12)( 0.09( 2.08( 0.27( 2.4((2.27,(2.61)(
(ug/L)( 16130( 0.24((0.22,(0.25)( 0.19( 1.90( 0.53( 2.3((2.01,(2.45)(
(
31145( 0.46((0.43,(0.48)( 0.38( 1.85( 0.93( 2.0((1.96,(2.19)(
(
46160( 0.74((0.71,(0.77)( 0.63( 1.78( 1.50( 2.0((1.95,(2.15)(
(
61+( 0.96((0.89,(1.03)( 0.82( 1.73( 1.98( 2.0((1.88,(2.21)(
( ( ( ( ( (PCB(153( 7114( 0.17((0.16,(0.18)( 0.13( 2.06( 0.43( 2.6((2.35,(2.82)(
(ug/L)( 16130( 0.37((0.35,(0.39)( 0.31( 1.90( 0.86( 2.3((2.08,(2.48)(
(
31145( 0.73((0.7,(0.77)( 0.61( 1.88( 1.46( 2.0((1.9,(2.12)(
(
46160( 1.19((1.15,(1.24)( 1.03( 1.77( 2.38( 2.0((1.93,(2.08)(
(
61+( 1.51((1.41,(1.63)( 1.32( 1.69( 3.11( 2.1((1.82,(2.39)(
( ( ( ( ( (PCB(180( 7114( 0.1((0.09,(0.1)( 0.07( 2.49( 0.28( 2.9((2.71,(3.11)(
(ug/L)( 16130( 0.21((0.2,(0.23)( 0.16( 2.11( 0.50( 2.4((2.25,(2.69)(
(
31145( 0.49((0.47,(0.52)( 0.40( 1.90( 1.02( 2.1((1.95,(2.17)(
(
46160( 0.85((0.82,(0.88)( 0.72( 1.83( 1.71( 2.0((1.92,(2.12)(
(
61+( 1.07((0.99,(1.15)( 0.91( 1.73( 2.09( 2.0((1.7,(2.21)(
( ( ( ( ( (DDE( 7114( 0.3((0.28,(0.33)( 0.21( 2.28( 0.91( 3.0((2.78,(3.54)(
(ug/L)( 16130( 1.04((0.96,(1.13)( 0.76( 2.15( 2.72( 2.6((2.36,(2.97)(
(
31145( 2.16((2.02,(2.32)( 1.43( 2.41( 6.73( 3.1((2.8,(3.63)(
(
46160( 3.52((3.25,(3.8)( 2.29( 2.58( 11.18( 3.2((2.84,(3.47)(
(
61+( 4.42((3.94,(4.94)( 3.10( 2.31( 13.37( 3.0((2.71,(3.29)(
( ( ( ( ( (HCB( 7114( 0.11((0.11,(0.11)( 0.10( 1.61( 0.20( 1.9((1.77,(2.03)(
(ug/L)( 16130( 0.21((0.19,(0.24)( 0.16( 2.01( 0.47( 2.2((2.05,(2.47)(
(
31145( 0.49((0.46,(0.54)( 0.34( 2.31( 1.31( 2.7((2.43,(3.19)(
(
46160( 1.05((0.99,(1.12)( 0.76( 2.35( 2.66( 2.5((2.3,(2.74)(
(





Compound( Age(Group( AM((95%CI)( GM( GSD( p95( P95:AM(ratio((95%(CI)(
PCB(138( 16130( 45.3((40.2,(51.1)( 33.1( 2.5( 101.3( 2.2((1.9,(3)(
(ng/g(lipid)( 31145( 74.2((65.9,(84.9)( 56.1( 2.4( 145.0( 2.0((1.8,(2.5)(
(
46160( 118.7((99,(149.6)( 90.7( 2.1( 235.4( 2.0((1.7,(2.4)(
(
60+( 145.2((127.4,(165.3)( 121.5( 1.8( 284.9( 2.0((1.5,(2.8)(
( ( ( ( ( (PCB(153( 16130( 60.6((54.5,(67.2)( 47.2( 2.3( 122.5( 2.0((1.8,(2.6)(
(ng/g(lipid)( 31145( 99.7((92.5,(108.4)( 84.2( 2.0( 209.4( 2.1((1.8,(2.3)(
(
46160( 149.5((136.5,(162.2)( 124.4( 2.1( 329.7( 2.2((1.9,(2.5)(
(
60+( 209.2((183,(238.8)( 171.9( 1.9( 528.5( 2.5((1.7,(2.9)(
( ( ( ( ( (PCB(180( 16130( 48.9((44.7,(54)( 40.7( 1.9( 98.7( 2((1.7,(2.4)(
(ng/g(lipid)( 31145( 83.1((77.3,(89.5)( 74.3( 1.6( 171.9( 2.1((1.8,(2.2)(
(
46160( 114.5((104.2,(125.5)( 99.0( 1.7( 228.9( 2((1.7,(2.2)(
(
60+( 149.8((131.3,(171.1)( 124.4( 1.7( 341.3( 2.3((1.7,(3.2)(
( ( ( ( ( (DDE( 16130( 262.9((219.1,(313.8)( 196.1( 2.0( 548.5( 2.1((1.9,(4)(
(ng/g(lipid)( 31145( 515.8((450,(595.1)( 373.7( 2.2( 1185.4( 2.3((2.1,(3)(
(
46160( 995.5((851.5,(1148.5)( 648.7( 2.6( 3532.4( 3.5((2.5,(4.1)(
(
60+( 1267.4((1079,(1478.7)( 878.6( 2.5( 3910.8( 3.1((2.4,(3.6)(
( ( ( ( ( (HCB( 16130( 88.1((73,(106.3)( 54.7( 3.0( 240.2( 2.7((2.2,(3.1)(
(ng/g(lipid)( 31145( 184.4((162,(211.2)( 106.0( 3.8( 472.0( 2.6((2.3,(3.1)(
(
46160( 375.8((329,(423.9)( 254.5( 2.7( 971.9( 2.6((2.2,(3)(
(
60+( 532((455,(610.2)( 383.7( 2.4( 1302.7( 2.4((2.1,(2.8)(




Table!S3:!!Arithmetic!mean!(AM),!geometric!mean!(GM),!geometric!standard!deviation!901! (GSD),!95th!percentile!(p95),!and!P95:AM!ratios!from!the!US!National!Health!and!Nutrition!902! Examination!Survey!(NHANES)!datasets.!!Summary!statistics!for!two!cycles!of!collection!for!903! PFOA!and!PFOS!are!presented:!!1999D2000,!and!2009D2010.!904!
Compound( Age(Group( AM((95%CI)( GM( GSD( p95( P95:AM(ratio((95%(CI)(
PCB(138( 12115( 5.8((4.6,(7)( 4.6( 1.9( 14.5( 2.5((2,(2.8)(
(ng/g(lipid)( 16130( 7.9((7.1,(8.8)( 6.4( 1.9( 18.8( 2.4((2.1,(2.8)(
(
31145( 18.1((15.7,(20.4)( 14.2( 2.0( 38.5( 2.1((2,(2.8)(
(
46160( 31.8((25,(38.5)( 25.2( 2.0( 75.8( 2.4((2.1,(3.1)(
( 60+( 52.4((45.7,(59.2)( 41.1( 2.0( 135.0( 2.6((2.4,(3.2)(
( ( ( ( ( ( (PCB(153( 12115( 7.4((5.8,(8.9)( 5.4( 2.0( 18.5( 2.5((2,(4)(
(ng/g(lipid)( 16130( 10.1((8.9,(11.3)( 7.9( 2.0( 21.9( 2.2((2,(2.9)(
(
31145( 23.2((20,(26.4)( 18.5( 2.0( 49.8( 2.1((2,(2.5)(
(
46160( 42.7((35,(50.5)( 34.7( 1.9( 103.0( 2.4((2.1,(2.9)(
( 60+( 68.8((60.8,(76.8)( 56.8( 1.8( 169.0( 2.5((2.2,(3.1)(
( ( ( ( ( ( (PCB(180( 12115( 4.9((3.7,(6.2)( 2.8( 2.7( 14.8( 3((2, 5.8)(
(ng/g(lipid)( 16130( 6.7((5.9,(7.5)( 4.8( 2.3( 18.5( 2.8((2.4,(3.5)(
(
31145( 19.5((16.1,(22.8)( 15.3( 2.0( 44.6( 2.3((2,(3.5)(
(
46160( 36((31.8,(40.3)( 30.9( 1.8( 75.8( 2.1((1.8,(2.6)(
( 60+( 57.9((50.6,(65.1)( 50.2( 1.7( 117.0( 2((1.9,(2.3)(
( ( ( ( ( ( (DDE( 12115( 195.5((123.5,(267.5)( 98.1( 2.7( 637.0( 3.3((2.3,(5.4)(
(ng/g(lipid)( 16130( 220.1((159,(281.1)( 125.5( 2.4( 577.0( 2.6((2,(3.2)(
(
31145( 409.2((288.9,(529.5)( 211.5( 2.6( 1020.0( 2.5((2.1,(3.2)(
(
46160( 602((415.5,(788.5)( 341.3( 2.8( 1870.0( 3.1((2.7,(3.7)(
( 60+( 1090.9((845.2,(1336.7)( 591.6( 3.2( 3970.0( 3.6((2.7,(4)(
( ( ( ( ( ( (HCB( 12115( 14.6((13.4,(15.7)( 13.1( 1.6( 27.4( 1.9((1.6,(2.6)(
(ng/g(lipid)( 16130( 14.3((13.2,(15.3)( 13.2( 1.4( 24.4( 1.7((1.6,(1.8)(
(
31145( 16.4((14.6,(18.2)( 14.7( 1.5( 26.5( 1.6((1.5,(1.8)(
(
46160( 17.5((16,(19)( 15.9( 1.5( 26.4( 1.5((1.4,(1.7)(
( 60+( 20.8((19.5,(22.1)( 19.2( 1.5( 37.4( 1.8((1.6,(2)(
( ( ( ( ( ( (PBDE(47( 12115( 43.2((35.2,(51.1)( 28.6( 2.5( 144.0( 3.3((2.3,(4.1)(
(ng/g(lipid)( 16130( 45.7((33.9,(57.6)( 24.3( 2.8( 146.0( 3.2((2.5,(4.2)(
(
31145( 40.3((23.3,(57.3)( 18.8( 2.9( 109.0( 2.7((1.9,(3.5)(
(
46160( 50((31.7,(68.3)( 18.5( 3.7( 240.0( 4.8((3.4,(7)(
( 60+( 51.1((33.7,(68.5)( 18.9( 3.8( 214.0( 4.2((3.3,(5)(
( ( ( ( ( ( (PFOA((09110)( 12115( 3((2.5,(3.4)( 2.7( 1.6( 5.3( 3((2.5,(3.4)(
(ng/ml)( 16130( 3.4((3,(3.8)( 2.9( 1.9( 7.0( 3.4((3,(3.8)(
(
31145( 3.3((2.9,(3.7)( 2.8( 1.9( 7.4( 3.3((2.9,(3.7)(
(
46160( 3.8((3.4,(4.2)( 3.3( 1.8( 7.6( 3.8((3.4,(4.2)(
( 60+( 4.2((3.6,(4.8)( 3.5( 1.9( 8.4( 4.2((3.6,(4.8)(
( ( ( ( ( ( (PFOS((09,(10)( 12115( 7.7((5.8,(9.7)( 6.4( 1.8( 18.1( 2.3((1.9,(3.1)(
(ng/ml)( 16130( 9.6((8,(11.2)( 7.6( 2.0( 20.0( 2.1((1.9,(2.5)(
(
31145( 10.5((7.9,(13.2)( 7.7( 2.2( 26.9( 2.6((2.2,(3)(
(
46160( 14((11.1,(16.9)( 10.7( 2.0( 32.2( 2.3((2,(3.2)(
( 60+( 18.5((14.5,(22.5)( 13.5( 2.2( 46.2( 2.5((2.3,(2.8)(
( ( ( ( ( ( (PFOA((99,(00)( 12115( 6.4((5.6,(7.1)( 5.8( 1.6( 11.9( 1.9((1.7,(2.7)(
(ng/ml)( 16130( 5.8((5.3,(6.4)( 5.2( 1.6( 11.0( 1.9((1.7,(2.2)(
(
31145( 6.4((4.9,(7.9)( 5.3( 1.7( 11.1( 1.7((1.5,(2.2)(
(
46160( 6.7((5.3,(8.1)( 5.4( 1.8( 14.6( 2.2((1.7,(2.6)(
( 60+( 5.8((4.4,(7.3)( 4.8( 1.9( 11.5( 2((1.7,(2.4)(
( ( ( ( ( ( (PFOS((99,(00)( 12115( 34.3((30.2,(38.3)( 31.3( 1.6( 57.6( 1.7((1.6,(1.9)(
(ng/ml)( 16130( 31.1((27.8,(34.5)( 27.7( 1.6( 56.8( 1.8((1.7,(2.2)(
(
31145( 36.2((28.9,(43.6)( 29.5( 1.8( 76.5( 2.1((1.8,(2.8)(
(
46160( 38.8((32.3,(45.3)( 33.2( 1.8( 78.3( 2((1.8,(2.6)(





Compound( Age(Group( AM((95%CI)( P95(
P95:AM(ratio(
(95%(CI)(
PCB(138( 16130( 6.1((4.7,(7.4)( 14( 2.3((2,(3.8)(
(ng/g(lipid)( 31145( 9.5((8.2,(11)( 24( 2.5((2.2,(2.7)(
(
46160( 19((16,(22)( 48( 2.6((2.3,(3.3)(
( 60+( 28((24,(33)( 68( 2.4((2.1,(2.8)(
( ( ( ( (PCB(153( 16130( 10((7.4,(14)( 28( 2.7((1.9,(3.8)(
(ng/g(lipid)( 31145( 17((14,(20)( 39( 2.3((2,(2.7)(
(
46160( 36((29,(43)( 96( 2.6((2.3,(3.5)(
( 60+( 55((48,(63)( 140( 2.5((2,(2.8)(
( ( ( ( (PCB(180( 16130( 7.7((4.5,(11)( 11a( 2.3((1.7,(4.2)(
(ng/g(lipid)( 31145( 14((11,(16)( 30( 2.2((2,(2.6)(
(
46160( 33((25,(41)( 11a( 2.3((2,(4.5)(
( 60+( 53((46,(60)( 140( 2.6((2,(3)(
( ( ( ( (DDE( 16130( 150((110,(200)( 11a( 3.2((2.7,(5.8)(
(ng/g(lipid)( 31145( 250((140,(350)( 11a( 3.6((2.1,(6)(
(
46160( 310((200,(420)( 1000( 3.2((2.6,(4.3)(
( 60+( 680((280,(1100)( 1600( 2.4((1.9,(3.8)(
( ( ( ( (HCB( 16130( 8.1((7.1,(9.1)( 16( 2((1.8,(2.3)(
(ng/g(lipid)( 31145( 12((9.5,(15)( 33( 2.7((1.8,(3.4)(
(
46160( 13((10,(16)( 26( 2((1.7,(2.3)(
( 60+( 17((14,(21)( 35( 2((1.6,(2.7)(
( ( ( ( (PBDE(47( 16130( 26((18,(34)( 100( 3.8((2.7,(5.8)(
(ng/g(lipid)( 31145( 16((13,(20)( 62( 3.8((2.9,(4.1)(
(
46160( 23((14,(32)( 62( 2.7((2.1,(3.5)(
( 60+( 24((17,(31)( 71( 3((2.5,(3.8)(
( ( ( ( (PFOA(( 16130( 2.9((2.7,(3.1)( 5.4( 1.9((1.7,(2)(
(ng/ml)( 31145( 2.7((2.5,(2.9)( 5.1( 1.9((1.8,(2)(
(
46160( 2.9((2.7,(3.1)( 5.5( 1.9((1.8,(2)(
( 60+( 3.2((3,(3.4)( 6.2( 2((1.8,(2.1)(
( ( ( ( (PFOS(( 16130( 10((9,(11)( 20( 1.9((1.8,(2.6)(
(ng/ml)( 31145( 11((8.8,(13)( 24( 2.2((1.9,(3.1)(
(
46160( 11((9.8,(12)( 29( 2.6((2.2,(2.9)(




Table!S5:!!Arithmetic!mean!(AM),!geometric!mean!(GM),!geometric!standard!deviation!910! (GSD),!and!95th!percentiles!(p95)!from!the!Flemish!Environment!and!Health!Survey!II!911! (FLEHS!II).!!P95:AM!ratios!were!not!calculated!for!this!dataset!because!it!was!used!as!a!912! validation!dataset.!913!
Compound( Age(Group( AM((95%(CI)( GM( GSD( p95(
( ( ( ( ( (PCB(138( Newborn( 20.1((18.6,(21.6)( 16.4( 2.0( 42.3(
(ng/g(lipid)( 13115( 13.3((12.3,(14.2)( 10.7( 1.9( 29.1(
(( 16130( 14.9((12,(17.9)( 12.2( 2.0( 39.9(
( ( ( ( ( (PCB(153( Newborn( 31.1((28.9,(33.3)( 26.4( 1.8( 66.4(
(ng/g(lipid)( 13115( 21.4((19.9,(22.8)( 17.4( 1.9( 45.6(
(( 16130( 23.3((19.3,(27.4)( 19.9( 1.8( 58.8(
( ( ( ( ( (PCB(180( Newborn( 18.4((16.9,(19.9)( 14.7( 2.0( 43.4(
(ng/g(lipid)( 13115( 12.8((11.7,(14)( 9.3( 2.2( 30.9(
(( 16130( 14((11.2,(16.8)( 11.2( 2.0( 38.5(
( ( ( ( ( (HCB( Newborn( 12.4((10.9,(13.9)( 9.4( 2.0( 26.9(
(ng/g(lipid)( 13115( 9.3((8.8,(9.9)( 8( 1.7( 16.7(
(( 16130( 8.2((7,(9.3)( 7.1( 1.8( 16(
( ( ( ( ( (DDE( Newborn( 101.3((90.4,(112.1)( 77.7( 2.0( 270.2(
(ng/g(lipid)( 13115( 84.1((69.6,(98.5)( 54.7( 2.2( 212.3(
(( 16130( 89((51,(127.1)( 55.4( 2.3( 484.3(
( ( ( ( ( (PBDE(47( Newborn( 11( 11( 11( 11(
(ng/g(lipid)( 13115( 0.7((0.6,(0.9)( 0.5( 2.0( 2.2(
(( 16130( 0.6((0.4,(0.8)( 0.4( 1.9( 3(
( ( ( ( ( (PFOA( Newborn( 1.6((1.5,(1.7)( 1.5( 1.5( 3(
(ug/L)( 13115( 2.6((2.5,(2.8)( 2.5( 1.3( 4(
(
16130( 3.4((3.1,(3.7)( 3.1( 1.6( 6.4(
( 31145( 3.5((3.3,(3.8)( 3.2( 1.6( 6.3(
( ( ( ( ( (PFOS( Newborn( 3.1((2.8,(3.3)( 2.6( 1.7( 5.7(
(ug/L)( 13115( 6.9((5.8,(7.9)( 5.6( 1.7( 13(
(
16130( 12.1((10.1,(14.2)( 10( 1.8( 29.6(
( 31145( 14.9((13.4,(16.4)( 12.7( 1.8( 32.4(!914! !915!
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